Primary renal glomus tumours of uncertain malignant potential: diagnostic challenges and insights from two instances.

BMJ Case RepSep 28, 2026 (epub)
Case ReportPathology (Anatomic & Clinical)Urology

Bhavika Sharma, Chippy Elizabeth Jose, Jyotsna Yesodharan et al.

✦ AI-curated · Sources linked

Case in brief

Two elderly patients presented with abdominal pain and were found to have large renal masses on imaging. Both underwent nephrectomy, and histopathological analysis revealed glomus tumors with atypical features but not meeting malignancy criteria. Postoperative follow-up showed a benign clinical course without local recurrence or metastasis.

Diagnostic / clinical pearl

Glomus tumors in the kidney, while rare, can present with atypical features that complicate diagnosis; however, they may still behave benignly despite these characteristics.

Source

PubMed · PMID 42805617

Published in BMJ Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pathology (Anatomic & Clinical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.